1. Effects of Niacin on Glucose Control in Patients With Dyslipidemia
Ronald B. Goldberg, MD, Terry A. Jacobson, MD 
Mayo Clinic Proceedings 
Volume 83, Issue 4, Pages (April 2008)
DOI: /
Copyright © 2008 Mayo Foundation for Medical Education and Research Terms and Conditions

2. FIGURE 1
Effects of niacin and placebo on fasting glucose over time in patients with or without diabetes mellitus. Between baseline and week 0, patients' regimens were titrated to 1 g/d. From week 0 to week 18, regimens were titrated from 1 g/d to 3 g/d. SI conversion factor: To convert glucose values to mmol/L, multiply by From JAMA,19 Copyright © 2000, with permission from the American Medical Association. All rights reserved.
Mayo Clinic Proceedings  , DOI: ( / )
Copyright © 2008 Mayo Foundation for Medical Education and Research Terms and Conditions

3. FIGURE 2
Effects of simvastatin-niacin (SN) and placebo on fasting glucose (top panels) and insulin (bottom panels) levels over time in patients with or without diabetes mellitus (DM). Post = up to 3 years. SI conversion factor: To convert glucose values to mmol/L, multiply by From Am J Cardiol,21 Copyright © 2004, with permission from Elsevier.
Mayo Clinic Proceedings  , DOI: ( / )
Copyright © 2008 Mayo Foundation for Medical Education and Research Terms and Conditions

4. FIGURE 3
Effects of niacin and placebo on postprandial glucose (mean 1-hour plasma glucose after a glucose load ≥180 mg/dL) (to convert to mmol/L, multiply by ). Closeout visit (CV) 2 was 4 months after CV 1. Only patients completing CV 2 were included. Data from reference 24.
Mayo Clinic Proceedings  , DOI: ( / )
Copyright © 2008 Mayo Foundation for Medical Education and Research Terms and Conditions

5. FIGURE 4
Effects of niacin and placebo on 6-year rate of myocardial infarction (MI) (A), 6-year rate of coronary artery disease (CAD) death or MI (B), and 15-year all-cause mortality rates (C) according to baseline levels of fasting glucose (FG). HR = hazard ratio. Z values based on test for homogeneity of treatment effect by FG were for MI, 0.47 for CAD death or MI, and for all-cause mortality, with values between and indicating homogeneity (no statistical differences) in HRs across FG levels. SI conversion factor: To convert glucose values to mmol/L, multiply by From Am J Cardiol,24 Copyright © 2005, with permission from Elsevier.
Mayo Clinic Proceedings  , DOI: ( / )
Copyright © 2008 Mayo Foundation for Medical Education and Research Terms and Conditions